Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials |
| |
| Authors: | Bo Liang Ning Gu |
| |
| Affiliation: | 1.Nanjing University of Chinese Medicine, Nanjing, China.;2.Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.;3.Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China. |
| |
| Abstract: | Heart failure coexists with type 2 diabetes mellitus, which seriously affects the clinical treatment and prognosis. At present, the treatment for patients with established heart failure and type 2 diabetes mellitus is usually combined with two treatment strategies for heart failure and type 2 diabetes mellitus. Recently, increasing studies showed that empagliflozin, a sodium-glucose co-transporter-2 inhibitor, has a positive effect on the treatment of patients with established heart failure and type 2 diabetes mellitus. Here, we summarize the latest and current understanding of the management for patients with established heart failure and type 2 diabetes mellitus and further present contemporary treatment options, sodium-glucose co-transporter-2 inhibitor, for these particular populations. |
| |
| Keywords: | empagliflozin SGLT2i heart failure type 2 diabetes mellitus |
|
|
